Galcanezumab for prevention of episodic and chronic migraine in real life in Colombia and Mexico: a multicenter prospective cohort study

被引：0

作者：

Munoz-Ceron, J. ^{[1
,2
]}

Velez, K. ^{[3
]}

Rodriguez, I. ^{[3
]}

Hernandez, N. ^{[4
]}

Guerra, C. ^{[4
,5
]}

Bohorquez, S. ^{[6
]}

Jimenez, J. D. ^{[7
]}

Moreno, C. ^{[2
,8
]}

Ramos, M. ^{[9
]}

Cavanzo, P. ^{[9
]}

Rojas, Y. ^{[10
]}

Bernal, R. ^{[10
]}

Lopez, R. ^{[11
]}

Gallo, L. ^{[1
]}

机构：

[1] Hosp Univ Mayor Mederi CIMED, Neurol, Bogota, Colombia

[2] Clin Univ Colombia Keralty, Bogota, Colombia

[3] Asociac Mexicana Cefaleas & MIgrana AC, Mexico City, DF, Mexico

[4] SURA, Medellin, Colombia

[5] Clin SOMA, Medellin, Colombia

[6] Hosp Kennedy, Bogota, Colombia

[7] ACN, Pereira, Colombia

[8] ACN, Bogota, Colombia

[9] ACN, Neurol, Bogota, Colombia

[10] ACN, Manizales, Colombia

[11] ACN, Medellin, Colombia

来源：

JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P255

引用

页数：2

共 50 条

[31] Sustained response of galcanezumab in migraine prevention: Patient--level data from a post hoc analysis in patients with episodic or chronic migraine
Tepper, Stewart J.
Dong, Yan
Vincent, Maurice
Wietecha, Linda A.
HEADACHE, 2023, 63 (10): : 1380 - 1390
[32] Real-Life Experience with Erenumab Therapy in the Episodic and Chronic Migraine
Alshawaf, Fatemah
Ahmed, Samar
Alroughani, Raed
Al-Hashel, Jasem
NEUROLOGY, 2023, 100 (17)
[33] Shift from Chronic to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab
Detke, Holland C.
Day, Kathleen A.
Lipsius, Sarah
Aurora, Sheena K.
Hindiyeh, Nada A.
Diener, Hans-Christoph
Nicholson, Robert
ANNALS OF NEUROLOGY, 2019, 86 : S245 - S245
[34] Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
Diener, Hans-Christoph
Day, Kathleen A.
Lipsius, Sarah
Aurora, Sheena K.
Hindiyeh, Nada A.
Detke, Holland C.
JOURNAL OF HEADACHE AND PAIN, 2025, 26 (01):
[35] Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Dodick, David W.
Doty, Erin G.
Aurora, Sheena K.
Ruff, Dustin D.
Stauffer, Virginia L.
Jedynak, Jakub
Dong, Yan
Pearlman, Eric M.
CEPHALALGIA, 2021, 41 (03) : 340 - 352
[36] Effectiveness of Galcanezumab on sleep, migraine and multidimensional patient-reperted outcome measures: A real-world experience in Turkish patients with episodic migraine and chronic migraine
Aydinlar, Elif Ilgaz
Soyukibar, Tuba Erdogan
Dikmen, Pinar Yalinay
CEPHALALGIA, 2023, 43 (1supp) : 243 - 243
[37] One-year safety and tolerability of erenumab in high-frequency episodic and chronic migraine in real-world: A multicenter, longitudinal, cohort study
Aurilia, C.
Egeo, G.
Fiorentini, G.
Cevoli, S.
Messina, R.
Salerno, A.
Torelli, P.
Albanese, M.
Carnevale, A.
Bono, F.
D'Amico, D.
Filippi, M.
Altamura, C.
Colombo, B.
Frediani, F.
Mercuri, B.
d'Onofrio, F.
Grazzi, L.
Aguggia, M.
Favoni, V
Di Fiore, P.
Finocchi, C.
Costa, C.
Brunelli, N.
Bertuzzo, D.
Zucco, M.
Di Clemente, L.
Trimboli, M.
Vernieri, F.
Barbanti, P.
HEADACHE, 2022, 62 : 115 - 116
[38] Medication overuse in a post-hoc analysis of phase 3 placebo controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Aurora, Sheena K.
Morrow, Paula A.
Ruff, Dustin D.
Pearlman, Eric
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[39] Galcanezumab shows efficacy as early as Day 1 after initial treatment v. placebo for the prevention of episodic and chronic migraine
Andreou, Anna P.
Wright, Peter
Detke, Holland C.
Ruff, Dustin
Reuter, Uwe
CEPHALALGIA, 2019, 39 (1_SUPPL) : 404 - 405
[40] Galcanezumab Shows Efficacy as Early as Day 1 After Initial Treatment vs. Placebo for the Prevention of Episodic and Chronic Migraine
Andreou, Anna P.
Wright, Peter
Detke, Holland
Ruff, Dustin
Reuter, Uwe
NEUROLOGY, 2020, 94 (15)

← 1 2 3 4 5 →